BridgeBio Pharma, Inc. (BBIO) Financial Statements

Executive TeamFinancials
SegmentsShareholders

BridgeBio Pharma financial statements at a glance

BridgeBio Pharma reported revenue of $502.08 million for fiscal year 2025 (ended December 31, 2025), up 126.3% from fiscal year 2024. Net income was -$724.93 million, a net margin of 144.4% loss, and diluted earnings per share were -$3.78.

At the end of fiscal year 2025 it had total assets of $936.03 million, total liabilities of $3.01 billion and shareholders' equity of -$2.09 billion, with cash and short-term investments of $587.48 million and total debt of $1.86 billion.

Its operations brought in -$445.91 million of cash; capital spending was $9.59 million, leaving free cash flow of -$455.50 million.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

BBIO logo

BridgeBio Pharma, Inc.

BBIOUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
502.08M
Prev Year: 221.90M
YoY: +126.3%
Operating Revenue
502.08M
Prev Year: 221.90M
YoY: +126.3%
Tax Effect of Unusual Items
-8.93M
Prev Year: 288.5K
YoY: -3193.5%
Total Unusual Items
-42.50M
Prev Year: 144.26M
YoY: -129.5%
Total Unusual Items Excluding Goodwill
-42.50M
Prev Year: 144.26M
YoY: -129.5%
Total Expenses
1.00B
Prev Year: 799.27M
YoY: +25.6%
Total Operating Income as Reported
-523.41M
Prev Year: -592.97M
YoY: +11.7%
Diluted NI Available to Com Stockholders
-724.93M
Prev Year: -535.76M
YoY: -35.3%
Special Income Charges
-42.50M
Prev Year: 136.13M
YoY: -131.2%
Other Special Charges
21.16M
Prev Year: 26.59M
YoY: -20.4%
Restructuring and Mergers Acquisition
21.35M
Prev Year: 15.33M
YoY: +39.2%
Equity in Earnings of Affiliates
-72.61M
Prev Year: -31.18M
YoY: -132.8%
Cost of Revenue
20.96M
Prev Year: 3.88M
YoY: +440.5%
Gross Profit
481.11M
Prev Year: 218.02M
YoY: +120.7%
Operating Expense
983.18M
Prev Year: 795.39M
YoY: +23.6%
Selling General and Administrative
531.23M
Prev Year: 288.93M
YoY: +83.9%
Research and Development
451.95M
Prev Year: 506.46M
YoY: -10.8%
Operating Income
-502.06M
Prev Year: -577.37M
YoY: +13.0%
Net Non Operating Interest Income Expense
-158.39M
Prev Year: -82.04M
YoY: -93.1%
Non-operating Interest Income
19.85M
Prev Year: 17.25M
YoY: +15.1%
Non-operating Interest Expense
178.24M
Prev Year: 99.29M
YoY: +79.5%
Otherunder Preferred Stock Dividend
-
Other Income Expense
-72.05M
Prev Year: 117.22M
YoY: -161.5%
Other Non-operating Income (expense)
43.06M
Prev Year: 4.14M
YoY: +941.1%
Gain on Sale of Securities
-
Prev Year: 8.14M
Pre-tax Income
-732.50M
Prev Year: -542.19M
YoY: -35.1%
Provision for Income Taxes
435.0K
Prev Year: 1.15M
YoY: -62.3%
Net Income Common Stockholders
-724.93M
Prev Year: -535.76M
YoY: -35.3%
Net Income
-724.93M
Prev Year: -535.76M
YoY: -35.3%
Net Income Including Non-Controlling Interests
-732.94M
Prev Year: -543.35M
YoY: -34.9%
Net Income from Continuing Operations
-732.94M
Prev Year: -543.35M
YoY: -34.9%
Noncontrolling Interests
8.01M
Prev Year: 7.58M
YoY: +5.6%
Basic EPS
-3.78
Prev Year: -2.88
YoY: -31.3%
Diluted EPS
-3.78
Prev Year: -2.88
YoY: -31.3%
Weighted Average Shares (basic)
191.53M
Prev Year: 186.08M
YoY: +2.9%
Weighted Average Shares (diluted)
191.53M
Prev Year: 186.08M
YoY: +2.9%
Net Income from Continuing and Discontinued Operation
-724.93M
Prev Year: -535.76M
YoY: -35.3%
Normalized Income
-691.35M
Prev Year: -679.74M
YoY: -1.7%
Interest Income
19.85M
Prev Year: 17.25M
YoY: +15.1%
Interest Expense
178.24M
Prev Year: 99.29M
YoY: +79.5%
Net Interest Income
-158.39M
Prev Year: -82.04M
YoY: -93.1%
EBIT
-554.26M
Prev Year: -442.90M
YoY: -25.1%
EBITDA
-548.83M
Prev Year: -436.83M
YoY: -25.6%
Reconciled Cost of Revenue
20.96M
Prev Year: 3.88M
YoY: +440.5%
Reconciled Depreciation
5.43M
Prev Year: 6.08M
YoY: -10.6%
Net Income from Continuing Operation Net Minority Interest
-724.93M
Prev Year: -535.76M
YoY: -35.3%
Normalized EBITDA
-506.33M
Prev Year: -581.09M
YoY: +12.9%
Tax Rate for Calcs
0.21
Prev Year: 0
Values in USD

BridgeBio Pharma key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$502.1M$221.9M$9.3M$77.6M$69.7M
Gross profit$481.1M$218.0M$6.9M$74.2M$66.6M
Operating income-$502.1M-$577.4M-$599.4M-$468.4M-$576.6M
Net income-$724.9M-$535.8M-$643.2M-$481.2M-$562.5M
Diluted EPS-$3.78-$2.88-$3.95-$3.26-$3.90
Total assets$936.0M$919.3M$546.4M$623.0M$1.0B
Total liabilities$3.0B$2.4B$1.9B$1.9B$1.9B
Shareholders' equity-$2.1B-$1.5B-$1.4B-$1.3B-$870.4M
Cash and short-term investments$587.5M$681.1M$434.9M$471.9M$836.7M
Total debt$1.9B$1.7B$1.7B$1.7B$1.7B
Operating cash flow-$445.9M-$520.7M-$527.7M-$419.5M-$497.9M
Capital spending$9.6M$8.9M$1.3M$6.3M$48.2M
Free cash flow-$455.5M-$529.6M-$529.0M-$425.8M-$546.2M

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2017.

Questions and answers

What was BridgeBio Pharma's revenue in fiscal year 2025?

$502.08 million, up 126.3% from $221.90 million in fiscal year 2024.

How much profit does BridgeBio Pharma make?

BridgeBio Pharma reported net income of -$724.93 million for fiscal year 2025 (144.4% of revenue); operating income was -$502.06 million.

How much cash and debt does BridgeBio Pharma have?

At the end of fiscal year 2025: cash and short-term investments of $587.48 million and total debt of $1.86 billion.

What is BridgeBio Pharma's free cash flow?

-$455.50 million in fiscal year 2025 (operating cash flow of -$445.91 million minus capital spending of $9.59 million).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube